Thursday, 5 November 2026European Markets

FINATIS Stock Slides By 19% In The Last 5 Sessions

Loading stream...

(vianews) - shares of finatis (cac 40: fnts.pa) dropped by a staggering 19.6% in 5 sessions from €5 to €4.02 at 14:54 est on wednesday, after five consecutive sessions in a row of losses. cac 40 is falling 0.59% to €7,326.38, after two consecutive sessions in a row of losses.

about finatis

finatis société anonyme operates in the food distribution business in france and latin america. it operates monoprix, franprix, casino supermarkets, petit casinos, casino shops, spars, vivals, géant hypermarkets, etc. the company also distributes sports equipment under the go sport brand; and invests in real estate properties, as well as manages a portfolio of private equity investments. the company was incorporated in 1971 and is headquartered in paris, france. finatis société anonyme is a subsidiary of euris sas.

earnings per share

as for profitability, finatis has a trailing twelve months eps of €-24.26.

volume

today's last reported volume for finatis is 48 which is 63.35% below its average volume of 131.

more news about finatis (fnts.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
FINATIS Stock Slides By 19% In The Last 5 Sessions | ViaNews EU